VFA
ELTX icon

Valeo Financial Advisors’s Elicio Therapeutics ELTX Stock Holding History

Valeo Financial Advisors’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,695
Closed -$21.4K – 627
2023
Q1 		$21.4K Hold
3,695
– – ﹤0.01% 599
2022
Q4 		$30K Sell
3,695
-2,671
-42% -$24.3K ﹤0.01% 522
2022
Q3 		$59K Hold
6,366
– – ﹤0.01% 475
2022
Q2 		$73K Hold
6,366
– – ﹤0.01% 465
2022
Q1 		$135K Buy
6,366
+4,001
+169% +$90.3K 0.01% 571
2021
Q4 		$69K Sell
2,365
-1,375
-37% -$69.5K ﹤0.01% 557
2021
Q3 		$365K Buy
+3,740
New +$404K 0.02% 361

Other funds holding ELTX

NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MHC
Meyer Handelman Company Rye Brook, New York $3.53B AUM 30.49% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Valeo Financial Advisors's ELTX Position: Q2 2023 in Review

Valeo Financial Advisors sold out of Elicio Therapeutics (ELTX) in Q2 2023, closing a stake of 3,695 shares — an estimated $21.4K sold.

Valeo Financial Advisors first reported a position in ELTX in Q3 2021 and held it in 7 quarters. The position peaked at $365K in Q3 2021. 15 funds tracked by Wall St. Rank hold ELTX as of Q2 2023.

  • Valeo Financial Advisors reported no remaining Elicio Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Valeo Financial Advisors sold 3,695 Elicio Therapeutics shares in Q2 2023, an estimated $21.4K.
  • Valeo Financial Advisors first reported a position in Elicio Therapeutics in Q3 2021 and held it in 7 quarters.
  • Valeo Financial Advisors's Elicio Therapeutics position peaked at $365K in Q3 2021.
  • 15 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2023.

Based on Valeo Financial Advisors's 13F filing for Q2 2023, filed 14 Jul 2023.